Literature DB >> 28450436

Noninvasive Assessment of IDH Mutational Status in World Health Organization Grade II and III Astrocytomas Using DWI and DSC-PWI Combined with Conventional MR Imaging.

Z Xing1, X Yang1, D She1, Y Lin1, Y Zhang1, D Cao2.   

Abstract

BACKGROUND AND
PURPOSE: Isocitrate dehydrogenase (IDH) has been shown to have both diagnostic and prognostic implications in gliomas. The purpose of this study was to examine whether DWI and DSC-PWI combined with conventional MR imaging could noninvasively predict IDH mutational status in World Health Organization grade II and III astrocytomas.
MATERIALS AND METHODS: We retrospectively reviewed DWI, DSC-PWI, and conventional MR imaging in 42 patients with World Health Organization grade II and III astrocytomas. Minimum ADC, relative ADC, and relative maximum CBV values were compared between IDH-mutant and wild-type tumors by using the Mann-Whitney U test. Receiver operating characteristic curve and logistic regression were used to assess their diagnostic performances.
RESULTS: Minimum ADC and relative ADC were significantly higher in IDH-mutated grade II and III astrocytomas than in IDH wild-type tumors (P < .05). Minimum ADC with the cutoff value of ≥1.01 × 10-3 mm2/s could differentiate the mutational status with a sensitivity, specificity, positive predictive value, and negative predictive value of 76.9%, 82.6%, 91.2%, and 60.5%, respectively. The threshold value of <2.35 for relative maximum CBV in the prediction of IDH mutation provided a sensitivity, specificity, positive predictive value, and negative predictive value of 100.0%, 60.9%, 85.6%, and 100.0%, respectively. A combination of DWI, DSC-PWI, and conventional MR imaging for the identification of IDH mutations resulted in a sensitivity, specificity, positive predictive value, and negative predictive value of 92.3%, 91.3%, 96.1%, and 83.6%.
CONCLUSIONS: A combination of conventional MR imaging, DWI, and DSC-PWI techniques produces a high sensitivity, specificity, positive predictive value, and negative predictive value for predicting IDH mutations in grade II and III astrocytomas. The strategy of using advanced, semiquantitative MR imaging techniques may provide an important, noninvasive, surrogate marker that should be studied further in larger, prospective trials.
© 2017 by American Journal of Neuroradiology.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28450436      PMCID: PMC7960080          DOI: 10.3174/ajnr.A5171

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  42 in total

Review 1.  Looking into the functional architecture of the brain with diffusion MRI.

Authors:  Denis Le Bihan
Journal:  Nat Rev Neurosci       Date:  2003-06       Impact factor: 34.870

2.  ADC values and prognosis of malignant astrocytomas: does lower ADC predict a worse prognosis independent of grade of tumor?--a meta-analysis.

Authors:  Maria Zulfiqar; David M Yousem; Hong Lai
Journal:  AJR Am J Roentgenol       Date:  2013-03       Impact factor: 3.959

3.  MRI apparent diffusion coefficient reflects histopathologic subtype, axonal disruption, and tumor fraction in diffuse-type grade II gliomas.

Authors:  Inas S Khayal; Scott R Vandenberg; Kenneth J Smith; Colleen P Cloyd; Susan M Chang; Soonmee Cha; Sarah J Nelson; Tracy R McKnight
Journal:  Neuro Oncol       Date:  2011-08-24       Impact factor: 12.300

4.  Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma.

Authors:  J A Carrillo; A Lai; P L Nghiemphu; H J Kim; H S Phillips; S Kharbanda; P Moftakhar; S Lalaezari; W Yong; B M Ellingson; T F Cloughesy; W B Pope
Journal:  AJNR Am J Neuroradiol       Date:  2012-02-09       Impact factor: 3.825

Review 5.  Molecular diagnostics of gliomas.

Authors:  Marina N Nikiforova; Ronald L Hamilton
Journal:  Arch Pathol Lab Med       Date:  2011-05       Impact factor: 5.534

Review 6.  Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician's perspective.

Authors:  Martin J van den Bent
Journal:  Acta Neuropathol       Date:  2010-07-20       Impact factor: 17.088

7.  Grading astrocytic tumors by using apparent diffusion coefficient parameters: superiority of a one- versus two-parameter pilot method.

Authors:  Ryuji Murakami; Toshinori Hirai; Takeshi Sugahara; Hirofumi Fukuoka; Ryo Toya; Shinichiro Nishimura; Mika Kitajima; Tomoko Okuda; Hideo Nakamura; Natsuo Oya; Jun-ichi Kuratsu; Yasuyuki Yamashita
Journal:  Radiology       Date:  2009-03-24       Impact factor: 11.105

8.  An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.

Authors:  Dan Rohle; Janeta Popovici-Muller; Nicolaos Palaskas; Sevin Turcan; Christian Grommes; Carl Campos; Jennifer Tsoi; Owen Clark; Barbara Oldrini; Evangelia Komisopoulou; Kaiko Kunii; Alicia Pedraza; Stefanie Schalm; Lee Silverman; Alexandra Miller; Fang Wang; Hua Yang; Yue Chen; Andrew Kernytsky; Marc K Rosenblum; Wei Liu; Scott A Biller; Shinsan M Su; Cameron W Brennan; Timothy A Chan; Thomas G Graeber; Katharine E Yen; Ingo K Mellinghoff
Journal:  Science       Date:  2013-04-04       Impact factor: 47.728

9.  Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.

Authors:  Christian Hartmann; Jochen Meyer; Jörg Balss; David Capper; Wolf Mueller; Arne Christians; Jörg Felsberg; Marietta Wolter; Christian Mawrin; Wolfgang Wick; Michael Weller; Christel Herold-Mende; Andreas Unterberg; Judith W M Jeuken; Peter Wesseling; Guido Reifenberger; Andreas von Deimling
Journal:  Acta Neuropathol       Date:  2009-06-25       Impact factor: 17.088

10.  Association between molecular alterations and tumor location and MRI characteristics in anaplastic gliomas.

Authors:  Yukihiko Sonoda; Ichiyoo Shibahara; Tomohiro Kawaguchi; Ryuta Saito; Masayuki Kanamori; Mika Watanabe; Hiroyoshi Suzuki; Toshihiro Kumabe; Teiji Tominaga
Journal:  Brain Tumor Pathol       Date:  2014-12-24       Impact factor: 3.154

View more
  31 in total

1.  Comparative study of pulsed-continuous arterial spin labeling and dynamic susceptibility contrast imaging by histogram analysis in evaluation of glial tumors.

Authors:  Atsuko Arisawa; Yoshiyuki Watanabe; Hisashi Tanaka; Hiroto Takahashi; Chisato Matsuo; Takuya Fujiwara; Masahiro Fujiwara; Yasunori Fujimoto; Noriyuki Tomiyama
Journal:  Neuroradiology       Date:  2018-04-29       Impact factor: 2.804

2.  Advanced imaging parameters improve the prediction of diffuse lower-grade gliomas subtype, IDH mutant with no 1p19q codeletion: added value to the T2/FLAIR mismatch sign.

Authors:  Min Kyoung Lee; Ji Eun Park; Youngheun Jo; Seo Young Park; Sang Joon Kim; Ho Sung Kim
Journal:  Eur Radiol       Date:  2019-08-24       Impact factor: 5.315

3.  A radiomics nomogram may improve the prediction of IDH genotype for astrocytoma before surgery.

Authors:  Yan Tan; Shuai-Tong Zhang; Jing-Wei Wei; Di Dong; Xiao-Chun Wang; Guo-Qiang Yang; Jie Tian; Hui Zhang
Journal:  Eur Radiol       Date:  2019-04-10       Impact factor: 5.315

Review 4.  Neuro-Oncology and Radiogenomics: Time to Integrate?

Authors:  A Lasocki; M A Rosenthal; S J Roberts-Thomson; A Neal; K J Drummond
Journal:  AJNR Am J Neuroradiol       Date:  2020-09-10       Impact factor: 3.825

5.  Conventional MRI features of adult diffuse glioma molecular subtypes: a systematic review.

Authors:  Arian Lasocki; Mustafa Anjari; Suna Ӧrs Kokurcan; Stefanie C Thust
Journal:  Neuroradiology       Date:  2020-08-25       Impact factor: 2.804

6.  Molecular Subtype Classification in Lower-Grade Glioma with Accelerated DTI.

Authors:  E Aliotta; H Nourzadeh; P P Batchala; D Schiff; M B Lopes; J T Druzgal; S Mukherjee; S H Patel
Journal:  AJNR Am J Neuroradiol       Date:  2019-08-14       Impact factor: 3.825

7.  Comparison of [18F]Fluoroethyltyrosine PET and Sodium MRI in Cerebral Gliomas: a Pilot Study.

Authors:  Aliaksandra Shymanskaya; Wieland A Worthoff; Gabriele Stoffels; Johannes Lindemeyer; Bernd Neumaier; Philipp Lohmann; Norbert Galldiks; Karl-Josef Langen; N Jon Shah
Journal:  Mol Imaging Biol       Date:  2020-02       Impact factor: 3.488

8.  Radiogenomics correlation between MR imaging features and major genetic profiles in glioblastoma.

Authors:  Eun Kyoung Hong; Seung Hong Choi; Dong Jae Shin; Sang Won Jo; Roh-Eul Yoo; Koung Mi Kang; Tae Jin Yun; Ji-Hoon Kim; Chul-Ho Sohn; Sung-Hye Park; Jae-Kyung Won; Tae Min Kim; Chul-Kee Park; Il Han Kim; Soon Tae Lee
Journal:  Eur Radiol       Date:  2018-05-02       Impact factor: 5.315

9.  Spatial discrimination of glioblastoma and treatment effect with histologically-validated perfusion and diffusion magnetic resonance imaging metrics.

Authors:  Melissa A Prah; Mona M Al-Gizawiy; Wade M Mueller; Elizabeth J Cochran; Raymond G Hoffmann; Jennifer M Connelly; Kathleen M Schmainda
Journal:  J Neurooncol       Date:  2017-09-12       Impact factor: 4.130

10.  Imaging prediction of isocitrate dehydrogenase (IDH) mutation in patients with glioma: a systemic review and meta-analysis.

Authors:  Chong Hyun Suh; Ho Sung Kim; Seung Chai Jung; Choong Gon Choi; Sang Joon Kim
Journal:  Eur Radiol       Date:  2018-07-12       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.